Economic challenges of oncological diseases' pharmacotherapy
Oncological diseases rank high in the structure of population morbidity and mortality. They entail considerable direct and indirect economic costs. In the past decades, the cost of oncotherapy has increased significantly, which is largely conditioned by high prices of antitumor drugs, which on avera...
Saved in:
Main Authors: | E. A. Ushkalova (Author), S. K. Zyryanov (Author), I. A. Gopienko (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020) -
Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach
by: A. G. Tolkushin, et al.
Published: (2019) -
Features of pharmacotherapy in the elderly patients. Introduction to the problem
by: E. A. Ushkalova, et al.
Published: (2016) -
PHARMACOTHERAPY OF ARTERIAL HYPERTENSION IN ELDERLY PATIENTS: FOCUS ON OCTOGENARIANS
by: E. A. Ushkalova, et al.
Published: (2016) -
Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease
by: S. K. Zyryanov, et al.
Published: (2021)